Key facts
- Notable investors include Northern Gritstone, King's College London, The University of Manchester.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Apini Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Apini Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Apini Therapeutics
Developer of small-molecule compounds designed for the treatment of chronic inflammatory diseases. The company's platform is designed to inhibit the pro-inflammatory activity of extracellular NAMPT (eNAMPT), focusing on cellular pathways involved in diseases such as diabetes, cardiovascular disease, and various forms of arthritis, enabling healthcare providers to address inflammatory conditions by targeting disease mechanisms at the molecular level.
- Sector
- Healthcare
- HQ
- Huntingdon, United Kingdom
- Founded
- 2021
- Employees
- 1
- Website
- apinitherapeutics.com/
- Ownership
- Privately Held (backing)
Apini Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apini Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apini Therapeutics in its N-PORT filings yet. We sweep new filings monthly.